NeuroOne Medical Technologies Corporation (NMTC)

Several events have impacted NMTC's stock price in the past six months. On August 14, 2025, NeuroOne reported its Q3 fiscal year 2025 earnings, with the stock drifting 4.8% higher over the subsequent 169 days. On May 13, 2025, the company reported its second-quarter fiscal year 2025 financial results, noting a significant year-over-year improvement in gross margin and announced the successful filing of an FDA submission for the OneRF® Trigeminal Nerve Ablation System. On January 10, 2025, NeuroOne announced preliminary unaudited revenue for Q1 fiscal 2025 of $6.2 million, leading to a 4.74% gain in NMTC's stock. On December 17, 2025, NMTC reported its Q4 2025 earnings per share (EPS) of -$0.04, meeting analysts' expectations. The stock's 52-week range has been between $0.40 and $1.25, with a closing stock price of $0.73 as of February 5, 2026.

Specific information detailing demand seasonality for NeuroOne Medical Technologies Corp.'s products and services is not explicitly provided; however, tools exist to analyze historical stock trading patterns around company-specific events and market economic reports to identify potential seasonal trends.

NeuroOne Medical Technologies Corp. is a medical technology company focused on developing and commercializing innovative solutions for neurological disorders, operating within the Health Care sector. They specialize in thin-film electrode technology to enhance patient outcomes through advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. Their major products include Evo Cortical Electrodes, Evo sEEG Electrodes, and the OneRF Ablation System. The company also explores applications in areas such as depression, mood disorders, incontinence, and artificial intelligence.

NeuroOne Medical Technologies Corp. is headquartered in Eden Prairie, Minnesota, and primarily provides its solutions for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording in the United States.

In the past year, NeuroOne Medical Technologies has secured significant media interest, including features on Fox News and Good Morning America in May 2025. The company has also received a consensus rating of "Moderate Buy" from analysts, with an average price target suggesting a significant upside potential from its current price.

The ownership structure of NeuroOne Medical Technologies (NMTC) stock is a mix of institutional, retail, and individual investors. Approximately 5.94% of the company's stock is owned by Institutional Investors, 11.39% by Insiders, and 82.67% by Public Companies and Individual Investors. LYTTON LAURENCE W is noted as owning the most shares of NeuroOne Medical Technologies.